16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hyperkalemia: pathophysiology, risk factors and consequences

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          There have been significant recent advances in our understanding of the mechanisms that maintain potassium homoeostasis and the clinical consequences of hyperkalemia. In this article we discuss these advances within a concise review of the pathophysiology, risk factors and consequences of hyperkalemia. We highlight aspects that are of particular relevance for clinical practice. Hyperkalemia occurs when renal potassium excretion is limited by reductions in glomerular filtration rate, tubular flow, distal sodium delivery or the expression of aldosterone-sensitive ion transporters in the distal nephron. Accordingly, the major risk factors for hyperkalemia are renal failure, diabetes mellitus, adrenal disease and the use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or potassium-sparing diuretics. Hyperkalemia is associated with an increased risk of death, and this is only in part explicable by hyperkalemia-induced cardiac arrhythmia. In addition to its well-established effects on cardiac excitability, hyperkalemia could also contribute to peripheral neuropathy and cause renal tubular acidosis. Hyperkalemia—or the fear of hyperkalemia—contributes to the underprescription of potentially beneficial medications, particularly in heart failure. The newer potassium binders could play a role in attempts to minimize reduced prescribing of renin–angiotensin inhibitors and mineraolocorticoid antagonists in this context.

          Related collections

          Most cited references68

          • Record: found
          • Abstract: found
          • Article: not found

          Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

          The Randomized Aldactone Evaluation Study (RALES) demonstrated that spironolactone significantly improves outcomes in patients with severe heart failure. Use of angiotensin-converting-enzyme (ACE) inhibitors is also indicated in these patients. However, life-threatening hyperkalemia can occur when these drugs are used together. We conducted a population-based time-series analysis to examine trends in the rate of spironolactone prescriptions and the rate of hospitalization for hyperkalemia in ambulatory patients before and after the publication of RALES. We linked prescription-claims data and hospital-admission records for more than 1.3 million adults 66 years of age or older in Ontario, Canada, for the period from 1994 through 2001. Among patients treated with ACE inhibitors who had recently been hospitalized for heart failure, the spironolactone-prescription rate was 34 per 1000 patients in 1994, and it increased immediately after the publication of RALES, to 149 per 1000 patients by late 2001 (P<0.001). The rate of hospitalization for hyperkalemia rose from 2.4 per 1000 patients in 1994 to 11.0 per 1000 patients in 2001 (P<0.001), and the associated mortality rose from 0.3 per 1000 to 2.0 per 1000 patients (P<0.001). As compared with expected numbers of events, there were 560 (95 percent confidence interval, 285 to 754) additional hyperkalemia-related hospitalizations and 73 (95 percent confidence interval, 27 to 120) additional hospital deaths during 2001 among older patients with heart failure who were treated with ACE inhibitors in Ontario. Publication of RALES was not associated with significant decreases in the rates of readmission for heart failure or death from all causes. The publication of RALES was associated with abrupt increases in the rate of prescriptions for spironolactone and in hyperkalemia-associated morbidity and mortality. Closer laboratory monitoring and more judicious use of spironolactone may reduce the occurrence of this complication. Copyright 2004 Massachusetts Medical Society
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Paleolithic nutrition. A consideration of its nature and current implications.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

              Hyperkalemia increases the risk of death and limits the use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) in high-risk patients. We assessed the safety and efficacy of patiromer, a nonabsorbed potassium binder, in a multicenter, prospective trial.
                Bookmark

                Author and article information

                Journal
                Nephrol Dial Transplant
                Nephrol. Dial. Transplant
                ndt
                Nephrology Dialysis Transplantation
                Oxford University Press
                0931-0509
                1460-2385
                December 2019
                04 December 2019
                04 December 2019
                : 34
                : Suppl 3 , Hyperkalemia: from pathophysiology to treatment
                : iii2-iii11
                Affiliations
                British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Queen’s Medical Research Institute , Edinburgh BioQuarter, Edinburgh, UK
                Author notes
                Correspondence to: Matthew A. Bailey; E-mail: Matthew.Bailey@ 123456ed.ac.uk ; Twitter handle: @edinburgh_renal
                Author information
                http://orcid.org/0000-0003-2344-8978
                http://orcid.org/0000-0003-4244-5668
                Article
                gfz206
                10.1093/ndt/gfz206
                6892421
                31800080
                768676c8-a3de-430f-a88d-73585abba315
                © The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 27 November 2018
                Page count
                Pages: 10
                Funding
                Funded by: Clinical Research Career Development Fellowship
                Funded by: Wellcome Trust 10.13039/100010269
                Award ID: 209562/Z/17/Z
                Funded by: Medical Research Council 10.13039/501100000265
                Award ID: MR/S01053X
                Funded by: British Heart Foundation 10.13039/501100000274
                Award ID: FS/18/57/34178
                Award ID: PG16/98/32568
                Funded by: Kidney Research UK 10.13039/501100000291
                Award ID: IN001/20170302
                Award ID: RP02/2019
                Funded by: Diabetes UK 10.13039/501100000361
                Award ID: 17/0005685
                Categories
                Reviews

                Nephrology
                aldosterone,arrhythmia,hyperkalemia,potassium,renin–angiotensin
                Nephrology
                aldosterone, arrhythmia, hyperkalemia, potassium, renin–angiotensin

                Comments

                Comment on this article